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Abstract: This study aims to evaluate the potential benefit of combination therapy of 
2-  methoxyestradiol (2ME) and magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) on myelo-
dysplastic syndrome (MDS) SKM-1 cells and its underlying mechanisms. The effect of the 
unique properties of tetraheptylammonium-capped MNPs-Fe3O4 with 2ME on cytotoxicity 
was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay. Cell-cycle 
  distribution and apoptosis were assessed by flow cytometry. The expression of cell-cycle 
marker protein was measured by Western blotting. Growth inhibition rate of SKM-1 cells treated 
with the 2ME-loaded MNPs-Fe3O4 was enhanced when compared with 2ME alone. 2ME led to 
an increase of caspase-3 expression, followed by apoptosis, which was significantly increased 
when combined with an MNPs-Fe3O4 carrier. Moreover, the copolymer of 2ME with MNPs-
Fe3O4 blocked a nearly two-fold increase in SKM-1 cells located in G2/M phase than in 2ME 
alone, which may be associated with an accompanying increase of p21 as well as a decrease in 
cyclin B1 and cdc2 expression, but there was no obvious difference between the MNPs-Fe3O4 
and control group. These findings suggest that the unique properties of MNPs-Fe3O4 as a carrier 
for 2ME, a new anticancer agent currently in clinical trials, may be a logical strategy to enhance 
the therapeutic activity of MDS.
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Introduction
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem-cell 
disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, 
and a propensity to transform to acute myeloid leukemia.1 Although new treatments 
for MDS are emerging, allogeneic stem-cell transplantation offers the only possible 
cure.2 Thus, there is an overwhelming need for new agents with more benign toxicity 
profiles and improved activity for the treatment of MDS.
The estrogen metabolite 2-methoxyestradiol (2ME) is a highly potent anticancer 
agent that effectively induces apoptosis in several cell lines, and several different 
proposed mechanisms have been investigated in vitro and in vivo.3–9 Notably, 2ME is 
not dependent on estrogen receptor binding, and has been found to be more toxic to 
leukemia cells than to their normal hematopoietic counterparts.10,11 However, up to 
now, 2ME-triggered cellular events are still not fully understood.
Nowadays, cancer therapy, particularly with respect to drug delivery, has evolved 
from traditional methodology.12 Nanotechnologies and nanoparticles are becoming a 
focus for human medical application for their unique properties.13 The diagnostic and 
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magnetic resonance imaging, hyperthermia techniques, cell 
separation, and tissue repair have expanded enormously 
in recent decades.14 The application of drug-coated poly-
mer nanospheres and nanoparticles to inhibit the related 
drug resistance has attracted much attention. The authors’ 
earlier studies as well as the studies of others have shown 
that magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4), as an 
anticancer drug deliverer,15 could enhance the sensitivity of 
anticancer drugs and reverse the drug resistance of tumor 
cells.16 Given that 2ME targets tumor cells specifically and 
possesses promising clinical activity, albeit with low bio-
availability, the authors of this present paper have explored 
a novel strategy to inhibit MDS cells by combining the 
unique properties of tetraheptylammonium-capped MNPs-
Fe3O4 with 2ME.
Materials and methods
Main materials
Iron chloride hexagydrate, iron sulfate heptahydrate, 
and ammonium hydroxide were supplied by Lingfeng 
Chemical Reagent Co Ltd (Shanghai, China); MTT 
(3-[4,5-  dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) and 2ME, by Sigma (St Louis, MO); Annexin 
V-FITC apoptosis detection kit, by Becton Dickin-
son (  Franklin Lakes, NJ); BCA protein assay kit, by 
  Biosynthesis   Biotechnology Co Ltd (Beijing, China); 
  anti-cyclin B1,   anti-cdc2,   anti-active caspase-3, and anti-
p21, by Cell Signaling Technology Inc (Danvers, MA); anti-
β-actin, by Santa Cruz   Biotechnology (Santa Cruz, CA); 
RPMI 1640, by Gibco BRL   (Gaithersburg, MD); and fetal 
bovine serum (FBS), by Sijiqing Co   (Hangzhou, China).
Preparation of 2Me-loaded MNPs-Fe3O4
MNPs-Fe3O4 was produced by electrochemical deposition 
under oxidizing conditions in a 0.1 M tetraheptylammonium 
2-propanol solution. The deposited clusters were capped 
with tetraheptylammonium, which acts as a stabilizer of 
the colloidal nanocrystallites.17 2ME was dissolved in 
absolute ethanol to give a 20 mM solution, and the final 
concentration of ethanol in the medium of 2ME-treated 
cells was adjusted to 0.1% (v/v).18 Before applied in this 
experiment, the prepared MNPs-Fe3O4 were well distrib-
uted in RPMI 1640 medium containing 10% (v/v) heat-
inactivated FBS by using ultrasound treatment in order 
to obtain an MNPs-Fe3O4 colloidal suspension. 2ME was 
conjugated with MNPs-Fe3O4 at the molar ratio of 100:1 by 
mechanical absorption polymerization at 4°C for 12 hours, 
as   previously reported.16
characteristic of MNPs-Fe3O4
To observe the particle size and morphology of MNPs-Fe3O4, 
the sample was dispersed in deionized water and measured 
using a JEM-2100 transmission electron microscope (JEOL, 
Tokyo, Japan). 
cell line and cell culture
SKM-1, an MDS cell line, was from the Japanese Collec-
tion of Research Bioresources Cell Bank.19 The cells were 
cultured in RPMI-1640 containing 10% FBS, 100 U/mL 
penicillin and 100 µg/mL streptomycin in an environment 
of saturated humidity, 5% CO2, and 37°C. The cells in the 
logarithmic growth phase were used in all experiments.
cell proliferation assay
As described previously,20 1 × 105 SKM-1 cells per well were 
incubated with either 2ME alone or loaded with MNPs-Fe3O4. 
After incubation for 12, 24, 48, and 72 hours, a 20 µL MTT 
solution (5 mg/mL) was added to each well at 37°C in the 
dark for at least 4 hours. Thereafter, the formazan crystals 
were solubilized in 200 µL dimethyl sulfoxide in every well, 
and the reduction of MTT was quantified using a Model 
550 microplate reader (Bio-Rad Laboratories, Tokyo, Japan). 
The inhibition ratio of cells was determined as follows 
(1 – Atest/Acontrol) × 100%.
Annexin V-PI assays for apoptosis
Cells were stained and evaluated for apoptosis by flow 
cytometry. After treatment for 24 hours as described above, 
SKM-1 cells were collected and washed twice with PBS, 
suspended in 200 µL binding buffer and 10 µL Annexin 
V-FITC for 20 minutes in the dark, and thereafter, 300 µL 
binding buffer and 5 µL propidium iodide (PI) were added 
to each sample. The apoptotic cells were determined using a 
flow cytometer (Becton Dickinson) with CellQuest (Becton 
Dickinson) software.
Analysis of cell cycle distribution
As described before, cells were harvested, washed with ice-
cold PBS, and stained with 50 µg/mL PI and 250 µg/mL 
RNase for 30 minutes. The percentage of cells in each 
phase of the cell cycle was determined with a computer-
programmed ModFit LT2.0 DNA assay (Becton Dickinson) 
using a flow cytometer.
Western blot analysis
Western blot assay was performed as previously described.16 
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and measured using BCA protein assay kit. Samples 
  containing 25 µg proteins were subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis and transferred 
to a nitrocellulose membrane. Nonspecific binding sites 
were blocked for 1 hour with 5% nonfat milk. The blots 
were stained with anti-p21, cyclin B1, cdc2 (1:200), or 
caspase-3 (1:400) antibodies overnight at 4°C, and then 
with a secondary horseradish peroxidase-conjugated goat 
antimouse antibody (1:5000) for 1 hour at room temperature. 
The blots were visualized by enhanced chemiluminescence 
(ECL system, Amersham, UK), and β-actin was used as the 
internal control.
statistical analysis
All data were presented as mean ± standard deviation in trip-
licate, and all analyses were performed with SPSS software 
(v 11.5; SPSS Inc, Chicago, IL). Statistical significance and 
differences observed between experimental groups were 
determined using Student’s t-test. P , 0.05 was considered 
significant.
Results
characteristics of MNPs-Fe3O4
The majority of MNPs-Fe3O4 were spherical, and particle 
sizes were 15.9 ± 4.6 nm (Figure 1).
Inhibition of cell proliferation
2ME significantly inhibited the growth of SKM-1 cells in a 
time- and dose-dependent manner (Figure 2). Notably, when 
2ME was loaded with MNPs-Fe3O4, the cell inhibition rate 
was increased (P , 0.05); however, MNPs-Fe3O4 alone 
did not generate significant cytotoxicity compared with the 
control group.
Induction of apoptosis
The percentage of apoptotic cells treated with 2ME alone or 
loaded with MNPs-Fe3O4 at 24 hours were higher than that 
in the control group. Notably, the apoptotic rate of the copo-
lymer was two-fold compared with 2ME alone (P , 0.05); 
however, there was no significant difference between the 
MNPs-Fe3O4 and control groups (P . 0.05) (Figure 3).
Distribution of cell cycle
Treatment of SKM-1 cells with 2ME alone for 24 hours 
resulted in a shift of cell distribution into the G2/M phase 
compared with the control group; interestingly, when the 
2ME was loaded with MNPs-Fe3O4, the number of cells 
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Figure 2 Proliferation inhibitory ratios of sKM-1 cells incubated with either 2Me 
alone or loaded with MNPs-Fe3O4 (100:1) for 12, 24, 48, and 72 hours.
Abbreviations: MNPs-Fe3O4, magnetic nanoparticles of Fe3O4; 2Me, 2-methoxy-
estradiol.
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Figure 3 Apoptosis of sKM-1 cells treated with either 2Me alone or loaded with MNPs-Fe3O4 (100:1) for 24 hours. (A) control. (B) MNPs-Fe3O4. (C) 2 µM 2Me. (D) 
copolymer of 2 µM 2Me with MNPs-Fe3O4 (100:1).
Abbreviations: MNPs-Fe3O4, magnetic nanoparticles of Fe3O4; 2ME, 2-methoxyestradiol; PI, propidium iodide; FITC, fluorescein isothiocyanate.
in the G2/M phase was increased from 34.9% ± 2.8% 
and 49.3% ± 3.1% to 70.8% ± 4.8% and 79.2% ± 5.1% 
for 1 and 2 µM 2ME, respectively, and in the G1 phase 
was decreased from 32.6% ± 2.5% and 21.0% ± 1.7% to 
12.2% ± 1.1% and 6.3% ± 1.5% for 1 and 2 µM 2ME, 
respectively, but there was no significant difference between 
MNPs-Fe3O4 and control group (P . 0.05; Figure 4).
expression of cell cycle proteins
The expressions of cdc2 and cyclin B1 in SKM-1 cells 
treated with 2ME for 24 hours were slightly downregulated 
compared with the control group, and the decrease was even 
more apparent when combined with MNPs-Fe3O4 (P , 0.05). 
In addition, the level of p21 was consistently increased after 
treatment with 2ME, and the increase was further augmented 
by addition of MNPs-Fe3O4 (P , 0.05). Similar results for 
caspase-3 were observed; conversely, there was no   obvious 
difference between MNPs-Fe3O4 and the control group 
(P . 0.05) (Figure 5).
Discussion
Recent exciting data suggest that nanomaterials have been 
successfully manipulated to create a new drug-delivery system 
that can not only solve the problem of poor water solubility of 
most promising currently available anticancer drugs but also 
reduce toxic side effects and, thereby, increase their effective-
ness. MNPs-Fe3O4, one of the most promising biocompatible 
materials, is feasible to produce, easy to functionalize, and not 
only shows satisfactory water solubilization and degradation in 
vivo but also improves the sensitivity of anticancer drugs.16,21 
In our study, the majority of synthesized MNPs-Fe3O4 were 
spherical and the average diameter size was 15.9 ± 4.6 nm, 
which is suitable for biological applications. Wang et al17 
demonstrate that the unique magnetic nanoparticles have a 
higher surface-to-volume ratio and a relatively smaller size, 
which could allow faster movement and easier entry into cells. 
Therefore, MNPs-Fe3O4 may offer an exciting nanomaterial 
toward developing an effective drug-delivery system for solv-
ing the solubility of 2ME.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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It is noteworthy that 2ME is considered to be a promising 
anticancer agent with several advantages in chemopreven-
tion as well as therapy.9,10,22 As we know, after the adsorption 
of the nanoparticles on the cellular membrane, the uptake 
occurs via several possible mechanisms such as pinocytosis, 
nonspecific or receptor-mediated endocytosis, or phagocy-
tosis.23 In our study, 2ME inhibited cell growth significantly 
in a dose- and time-dependent manner, which is consistent 
with studies in multiple myeloma.24   Interestingly, the 
growth inhibition rate was augmented by the MNPs-Fe3O4, 
while there was no significant influence on SKM-1 cells by 
MNPs-Fe3O4 alone. Moreover, literature reports that the 
chemotherapeutic drug-coated poly (methacrylate) nano-
sphere composite could be internalized by an endocytotic 
process, and this process can cause higher intracellular 
drug accumulation.17 Thus, we infer that MNPs-Fe3O4 can 
increase the sensitivity of SKM-1 cells to 2ME via altering 
the pharmacokinetics of 2ME.
Cell growth is tightly regulated by cell-cycle checkpoints. 
It is worth noting that 2ME has been shown to block many 
human hematologic cell lines25 and other cells3 in the G2/M 
phase in vitro. In our study, 2ME resulted in a shift of cell 
distribution into the G2/M phase, and this shift was enhanced 
by MNPs-Fe3O4, while some other researchers reported that 
2ME arrested cells in G1/S,9 or both G1/S and G2/M.5 These 
opposing results suggest that there may be fundamental 
differences between cell types. Our data indicated that the 
copolymer of 2ME with MNPs-Fe3O4 results in cell-cycle 
block in the G2/M phase, thereby decelerating proliferation; 
further studies should be investigated to establish whether 
the 2ME-induced accumulation of SKM-1 cells is due to a 
specific block in G2 or in the M phase.
Evidence in the literature suggests that the progression 
through the cell cycle is regulated by different types of cyclins 
and several different cyclin-dependent kinases (CDKs),26 and 
the activities of CDKs are responsible for phosphorylation 
of downstream targets, while the cyclin-dependent kinase 
inhibitors are the key players in the negative regulation of 
the cell cycle in response to a wide variety of antiproliferative 
signals. Among several CDK inhibitors, p21 is one of the 
important inhibitory proteins in the G2/M checkpoint, which 
can inactivate the cdc2–cyclinB1 complex, thus evoking cell 
cycle arrest.27 The results of this present study showed that 
2ME decreased the expression of cyclin B1 and cdc2, whereas 
it induced an increase in expression of p21, and this effect 
was augmented by the carrier of MNPs-Fe3O4. These data 
and other studies incuding Barboule et al3 suggest that p21 is 
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Figure 4 cell-cycle distributions after treatment with either 2Me alone or loaded with MNPs-Fe3O4 (100:1) for 24 hours. (A) control group. (B) MNPs-Fe3O4 alone. (C) 
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involved in the cyclin–cdc machinery during the G2/M-phase 
cell-cycle arrest in response to the copolymer of 2ME with 
MNPs-Fe3O4 in SKM-1 cells.
The authors of this paper are investigating the molecular 
mechanisms involved in mediating 2ME-induced cell apop-
tosis. The results showed that SKM-1 cells underwent typical 
apoptotic changes as indicated by flow cytometry, which 
is consistent with previous trials.4–8 Caspase-3 is a critical 
mediator of apoptosis, which is responsible for the proteolytic 
cleavage of many key proteins such as the nuclear enzyme 
poly (ADP- ribose) polymerase (PARP).28 2ME in this study 
increased the expression of caspase-3, and the increase was 
further augmented by MNPs-Fe3O4, implicating the role of 
active caspase-3 in SKM-1 cells. It is well established that 
p21 is not only involved in cell-cycle arrest, but also involved 
in the induction of apoptosis.3,6,29 2ME induced the increase 
of p21 in this study, which is inconsistent with the results 
of Zhou et al,4 suggesting that it depends on the cellular 
context whether p21 participates in regulating apoptotic 
function in response to 2ME. Therefore, we cannot exclude 
the possibility that some other mechanism participates in the 
2ME-induced apoptosis. Overall, the results of this study 
revealed that the copolymer of 2ME with MNPs-Fe3O4 which 
prolongs cell-cycle arrest, can lead to cell death, mediated by 
the activation of the intrinsic pathway of apoptosis.
Conclusion
These results indicate that the unique properties of MNPs-
Fe3O4 as a carrier for 2ME, a new anticancer agent currently 
in clinical trials, may be a logical strategy to enhance thera-
peutic activity of MDS.
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